EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Targeting B‐Cell‐Activating Factor and Its Receptor in Immune Thrombocytopenia and Warm Autoimmune Hemolytic Anemia

Matthieu Mahévas iD, Nichola Cooper iD, Vickie McDonald iD, Karina Yazdanbakhsh iD, Wilma Barcellini iD

American Journal of Hematology · 2026

DOI: 10.1002/ajh.70460 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift American Journal of Hematology, 2026. Verfasst von Matthieu Mahévas und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, National Referral Center for Autoimmune Cytopenias, Créteil University Hospital, Créteil, France. Hauptthemen laut MEDLINE: Anemia, Hemolytic, Autoimmune, B-Cell Activating Factor, Purpura, Thrombocytopenic, Idiopathic, B-Cell Activation Factor Receptor. Die Arbeit nennt 138 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Novartis Pharmaceuticals Corporation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Current treatments for immune thrombocytopenia (ITP) and warm autoimmune hemolytic anemia (wAIHA), rare autoimmune diseases in which autoreactive B cells play a major role, can lead to high response rates; however, for many patients these responses are not durable or maintained after treatment discontinuation. Binding of B‐cell‐activating factor (BAFF) to its receptor (BAFF‐R) has been shown to lead to B‐cell differentiation, proliferation, and survival, with BAFF levels shown to be elevated in patients with ITP and wAIHA. Targeting the BAFF/BAFF‐R pathway could address unmet needs that remain for patients with ITP and wAIHA despite available treatments.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anemia, Hemolytic, AutoimmuneB-Cell Activating FactorPurpura, Thrombocytopenic, IdiopathicB-Cell Activation Factor ReceptorHumansB-Lymphocytes

Stichwörter der Autor:innen

BAFFBAFF‐RB‐cell‐activating factorB‐cell‐activating factor receptorimmune thrombocytopeniawarm autoimmune hemolytic anemia

Substanzen

B-Cell Activating FactorB-Cell Activation Factor ReceptorTNFSF13B protein, human

Autor:innen und Institutionen

  • Department of Internal Medicine, National Referral Center for Autoimmune Cytopenias, Créteil University Hospital, Créteil, France.
  • Department of Inflammation and Immunity, Imperial College London, London, UK.
  • Department of Clinical Haematology, Guy's and St Thomas' NHS Foundation Trust, London, UK.
  • Lindsley F Kimball Research Institute, New York Blood Center, New York, New York, USA.
  • Department of Hematology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.

ORCID-Profile: Matthieu Mahévas, Nichola Cooper, Vickie McDonald, Karina Yazdanbakhsh, Wilma Barcellini

Förderung

  • Novartis Pharmaceuticals Corporation

Zitieren

APA

Mahévas, M., Cooper, N., McDonald, V., Yazdanbakhsh, K., & Barcellini, W. (2026). Targeting B‐Cell‐Activating Factor and Its Receptor in Immune Thrombocytopenia and Warm Autoimmune Hemolytic Anemia. American Journal of Hematology. https://doi.org/10.1002/ajh.70460

Vancouver

Mahévas M, Cooper N, McDonald V, Yazdanbakhsh K, Barcellini W. Targeting B‐Cell‐Activating Factor and Its Receptor in Immune Thrombocytopenia and Warm Autoimmune Hemolytic Anemia. American Journal of Hematology. 2026. doi:10.1002/ajh.70460

BibTeX
@article{Mahvas2026,
  author = {Mahévas, Matthieu and Cooper, Nichola and McDonald, Vickie and Yazdanbakhsh, Karina and Barcellini, Wilma},
  title = {Targeting B‐Cell‐Activating Factor and Its Receptor in Immune Thrombocytopenia and Warm Autoimmune Hemolytic Anemia},
  journal = {American Journal of Hematology},
  year = {2026},
  doi = {10.1002/ajh.70460}
}
Kostenlos starten →